For the readers interested in the stock health of Bristol-Myers Squibb Company (BMY). It is currently valued at $61.41. When the transactions were called off in the previous session, Stock hit the highs of $59.64, after setting-off with the price of $59.19. Company’s stock value dipped to $58.84 during the trading on the day. When the trading was stopped its value was $59.49.
Recently in News on November 3, 2020, Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla® (apremilast) in Pivotal Phase 3 Psoriasis Study. Superiority of deucravacitinib was demonstrated on both co-primary endpoints and multiple key secondary endpoints in the POETYK PSO-1 trial. You can read further details here
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
Bristol-Myers Squibb Company had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $68.34 on 01/22/20, with the lowest value was $45.76 for the same time period, recorded on 03/23/20.
Bristol-Myers Squibb Company (BMY) full year performance was 4.08%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Bristol-Myers Squibb Company shares are logging -10.14% during the 52-week period from high price, and 34.20% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $45.76 and $68.34.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2379635 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Bristol-Myers Squibb Company (BMY) recorded performance in the market was -7.32%, having the revenues showcasing 0.03% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 132.87B, as it employees total of 30000 workers.
Analysts verdict on Bristol-Myers Squibb Company (BMY)
During the last month, 10 analysts gave the Bristol-Myers Squibb Company a BUY rating, 3 of the polled analysts branded the stock as an OVERWEIGHT, 5 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 59.80, with a change in the price was noted +5.24. In a similar fashion, Bristol-Myers Squibb Company posted a movement of +9.34% for the period of last 100 days, recording 10,970,812 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BMY is recording 0.95 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.85.
Bristol-Myers Squibb Company (BMY): Technical Analysis
Raw Stochastic average of Bristol-Myers Squibb Company in the period of last 50 days is set at 70.49%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 82.24%. In the last 20 days, the company’s Stochastic %K was 53.49% and its Stochastic %D was recorded 35.22%.
Let’s take a glance in the erstwhile performances of Bristol-Myers Squibb Company, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -7.32%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -3.05%, alongside a boost of 4.08% for the period of the last 12 months. The shares increased approximately by -0.30% in the 7-day charts and went down by 1.31% in the period of the last 30 days. Common stock shares were driven by 0.03% during last recorded quarter.